Determination of the Origin of Charge Heterogeneity in a Murine Monoclonal Antibody

AbstractPurpose. The aim of this study was to elucidate the molecular basis of charge heterogeneity found in a purified monoclonal IgG1 antibody, MMA383. Methods. Cation exchange chromatography (CEX) and isoelectric focusing (IEF) were used to monitor charge heterogeneity. CEX in conjunction with carboxypeptidase B digests of the antibody was used to determine the contribution of C-terminal lysines to MMA383 charge heterogeneity. Potential chemical degradation sites were identified by peptide mapping of individual chains, with peptide identification by mass spectrometry (MALDI-TOF MS). Peptide sequencing was used to determine specific deamidation sites. Binding constants of predominant isoforms were compared by surface plasmon resonance (SPR). Results. Extensive charge heterogeneity of purified MMA383 was detected by CEX and IEF. Removal of C-terminal lysines simplified the IEF pattern to nine predominant isoforms. Quantitation of isoaspartate in each of the isoforms indicated deamidation of MMA383 as a major cause of charge heterogeneity. CEX of the individual isoform chains suggested the presence of one deamidation site on each of the heavy and light chains. The two sites of deamidation were identified using peptide mapping, sequencing and mass spectrometry. SPR results showed no significant difference in the binding parameters among the isoforms. Conclusions. C-terminal lysine microheterogeneity and deamidation of Asn141 in the heavy chain and Asn161 in the light chain are the major causes of MMA383 charge heterogeneity. Identification of the two deamidation sites will allow replacement of these amino acids in order to create a product less susceptible to degradation.

[1]  F. Westall.  Released myelin basic protein: the immunogenic factor? , 1974, Immunochemistry.

[2]  A. Klibanov,et al.  The mechanisms of irreversible enzyme inactivation at 100C. , 1985, Science.

[3]  I. Pastan,et al.  Treatment of advanced solid tumors with immunotoxin LMB–1: An antibody linked to Pseudomonas exotoxin , 1996, Nature Medicine.

[4]  R. Borchardt,et al.  Stability of Protein Pharmaceuticals , 1989, Pharmaceutical Research.

[5]  R J Harris,et al.  Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. , 1995, Journal of chromatography. A.

[6]  A. Kossiakoff,et al.  Tertiary structure is a principal determinant to protein deamidation. , 1988, Science.

[7]  H. Wright.  Sequence and structure determinants of the nonenzymatic deamidation of asparagine and glutamine residues in proteins. , 1991, Protein engineering.

[8]  R. Jefferis,et al.  A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. , 1990, The Biochemical journal.

[9]  G. Ragupathi.  Carbohydrate antigens as targets for active specific immunotherapy , 1996, Cancer Immunology, Immunotherapy.

[10]  J Navaza,et al.  Three-dimensional structures of the free and the antigen-complexed Fab from monoclonal anti-lysozyme antibody D44.1. , 1994, Journal of molecular biology.

[11]  R Tyler-Cross,et al.  Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides. , 1991, The Journal of biological chemistry.

[12]  D. Buchanan,et al.  Beta-aspartyl peptides in enzymatic hydrolysates of protein. , 1966, Biochemistry.

[13]  S. Clarke.  Propensity for spontaneous succinimide formation from aspartyl and asparaginyl residues in cellular proteins. , 2009, International journal of peptide and protein research.

[14]  G. Allen,et al.  Sequencing of proteins and peptides , 1981 .

[15]  P. Bornstein,et al.  [14] Cleavage at AsnGly bonds with hydroxylamine , 1977 .

[16]  P. Chapman.  Anti-idiotypic monoclonal antibody cancer vaccines. , 1995, Seminars in cancer biology.

[17]  S. Clarke,et al.  Succinimide formation from aspartyl and asparaginyl peptides as a model for the spontaneous degradation of proteins. , 1989, The Journal of biological chemistry.

[18]  L. Presta,et al.  Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity. , 1996, Biochemistry.

[19]  D. Volkin,et al.  Degradative covalent reactions important to protein stability. , 1997, Methods in molecular biology.

[20]  R. Jefferis,et al.  Glycosylation of antibody molecules: structural and functional significance. , 1996, Chemical immunology.

[21]  Daniel J. Kroon,et al.  Identification of Sites of Degradation in a Therapeutic Monoclonal Antibody by Peptide Mapping , 1992, Pharmaceutical Research.